Actinium Pharmaceuticals, Inc (Actinium)

Oncology Corporate Profile

HQ Location

501 Fifth Avenue
New York, NY 10017

Company Description

Actinium Pharmaceuticals, Inc. is a public biopharmaceutical company specialized in the development of cancer drugs. The Company's product candidates are based on its patented technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC) for combining the cancer targeting precision of monoclonal antibodies (mAb) for targeting specific types of cells with the power of alpha emitting radioisotopes, the most potent cancer killing agents in existence. API's first drug for the treatment of acute myeloid leukemia (AML) has been administered to 49 patients with promising results and the second generation drug candidate is currently in clinical trials with 28 patients treated to date. In addition to leukemia drugs, API's technology has been used to produce drug candidates for treatment of metastatic colorectal and prostate cancers, antiangiogenesis (prevention of blood supply to and growth of many solid cancers) and bone marrow ablation, part of a curative treatment for leukemias, lymphomas and multiple myeloma.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Iomab-B CD45monoclonal antibodyAcute Myelogenous Leukemia (AML)III
Actimab-A CD33monoclonal antibodyAcute Myelogenous Leukemia (AML)II
Actimab-M CD33monoclonal antibodyMultiple MyelomaI
Actimab-Cmonoclonal antibodyColorectal cancerPreclinical
Actimab-Brmonoclonal antibodyGlioblastoma Multiforme (GBM)Preclinical
Actimab-Pmonoclonal antibodyProstate cancerPreclinical

View additional information on product candidates here »


Recent News Headlines

There are no news items to display